Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy.
Journal: Journal for immunotherapy of cancer
Published: May 26, 2023
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Journal: Nature medicine
Published: March 19, 2021
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Journal: Haematologica
Published: March 27, 2018
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Journal: Blood
Published: May 16, 2017
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: October 06, 2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Journal: Blood
Published: July 07, 2016
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 16, 2015
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Journal: Cancer chemotherapy and pharmacology
Published: April 25, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026